Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04543071 | Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma | PHASE2 | RECRUITING | 10 | — | — | Nov 9, 2020 | Aug 1, 2028 | Jun 19, 2025 | 3 | United States |
Complete response is defined as the disappearance of all lesions. Partial response is defined as ≥30% decrease in the sum of diameters of target lesions, in the absence of CR, new lesions, and unequivocal progression in non-target lesions.
| Arm | Type | Description |
|---|---|---|
| Motixafortide, Cemiplimab, Gemcitabine, Nab-Paclitaxel | EXPERIMENTAL | Participants will receive standard FDA-approved doses of gemcitabine and nab-paclitaxel for pancreas cancer and cemiplimab at the dose that is approved for participants with skin cancer. Participants will also receive motixafortide at a dose that has been deemed safe in previous studies when used in combination with immunotherapy and chemotherapy. If the combination study treatment causes a serious side effect in participants, the study treatment will be modified. |
| Name | Type | Description |
|---|---|---|
| Motixafortide | DRUG | 1.25 mg/kg subcutaneous (SC) monotherapy daily for 5 days during priming, followed by twice weekly |
| Cemiplimab | DRUG | 350 mg intravenous (IV) once every 21 days |
| Gemcitabine | DRUG | 1000 mg/m2 IV on days days 1, 8, 14 (every 28 days) |
| Nab paclitaxel | DRUG | 125 mg/m2 IV on days 1, 8, 14 (every 28 days) |
Inclusion criteria: 1. Histological or pathological confirmation of metastatic pancreas adenocarcinoma 1. Cytologic or histologic proof of pancreas adenocarcinoma needs to be verified by the treating institution pathologist, either from the initial diagnostic biopsy or from the required pre-tre...